EGFR and colorectal carcinoma: More than 90% of CRC patients overexpress EGFR, so it is necessary to further explore the molecular biological mechanism of EGFR-positive CRC and identify more precise biomarkers to improve the effectiveness of individualized treatment strategies (Morgan et al., 2018).